THOR - Clinical Data Making A Stronger Case For Nektar Therapeutics

I’ve been what I’d call “cautiously bullish” on Nektar (NKTR) and its lead drug bempegaldesleukin (formerly known as NKTR-214, I’m going with “bempeg” for short); while the idea of a safer form of IL-2 to accompany PD-1 antibodies and other established cancer therapies is appealing, the initial data were mixed and the shares are down almost 50% from when I last wrote about the company.

I don’t think is exclusively a Nektar issue, as the infamous blow-up of Incyte’s (INCY) melanoma drug epacadostat made investors more skeptical about melanoma treatments,

Read more ...